The Stock2Me Podcast

Stock2Me’s latest podcast features Paul Duffy, President of Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF).

During the interview, Duffy explains how the company’s technology uses your smartphone to “augment” your view by superimposing a hologram into your physical location.

“What makes us different is that we put augmented reality into everything that we do. AR is the ability to take photorealistic objects – it could be people, products or places – and superimpose them using your smartphone,” Duffy said. “So, as you view your phone over a location you can conjure up a hologram and literally augment the reality of that space. If you want to view a vacuum cleaner, you could literally press a button on our website, and it will conjure up through your browser that particular vacuum as a hologram. You can pinch it, zoom it, rotate it, put it in your closet and take a selfie to send to your partner and say, ‘That’s the one we want to buy.’ AR is very useful in converting online shoppers into buyers.”

Stock2Me’s latest podcast features Paul Duffy, President of Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF).

During the interview, Duffy explains how the company’s technology uses your smartphone to “augment” your view by superimposing a hologram into your physical location.

“What makes us different is that we put augmented reality into everything that we do. AR is the ability to take photorealistic objects – it could be people, products or places – and superimpose them using your smartphone,” Duffy said. “So, as you view your phone over a location you can conjure up a hologram and literally augment the reality of that space. If you want to view a vacuum cleaner, you could literally press a button on our website, and it will conjure up through your browser that particular vacuum as a hologram. You can pinch it, zoom it, rotate it, put it in your closet and take a selfie to send to your partner and say, ‘That’s the one we want to buy.’ AR is very useful in converting online shoppers into buyers.”

Stock2Me’s latest podcast features Staci Wallace, leading expert in the fields of business psychology and process strategy. Wallace helps business owners, leaders and entrepreneurs learn essential hacks to build a life and a business they love. For over 30 years in corporate America, she has been effectively shifting mindsets into greater outcomes as an engaging speaker, thought leader, business executive and author of eight books, including her latest, Fueled by Fire, now available on Amazon. She is also host of the Comeback Small Business Radio Show and holds a black belt in mixed martial arts.

Stock2Me’s latest podcast features Staci Wallace, leading expert in the fields of business psychology and process strategy. Wallace helps business owners, leaders and entrepreneurs learn essential hacks to build a life and a business they love. For over 30 years in corporate America, she has been effectively shifting mindsets into greater outcomes as an engaging speaker, thought leader, business executive and author of eight books, including her latest, Fueled by Fire, now available on Amazon. She is also host of the Comeback Small Business Radio Show and holds a black belt in mixed martial arts.

Stock2Me’s latest podcast features Lomit Patel, expert in AI and early-stage business growth. Patel is Vice President of Growth at IMVU. He previously managed growth at startups including Roku; TrustedID, which was acquired by Equifax; Texture, which was acquired by Apple; and EarthLink. Patel is a public speaker, author and advisor, and he is recognized as a Mobile Hero by Liftoff. His new bestselling book “Lean AI: How Innovative Startups Use Artificial Intelligence to Grow” is part of Eric Ries’ “The Lean Startup” series, now available on Amazon.

Stock2Me’s latest podcast features Lomit Patel, expert in AI and early-stage business growth. Patel is Vice President of Growth at IMVU. He previously managed growth at startups including Roku; TrustedID, which was acquired by Equifax; Texture, which was acquired by Apple; and EarthLink. Patel is a public speaker, author and advisor, and he is recognized as a Mobile Hero by Liftoff. His new bestselling book “Lean AI: How Innovative Startups Use Artificial Intelligence to Grow” is part of Eric Ries’ “The Lean Startup” series, now available on Amazon.

The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me’s latest podcast features Ian Rosen, fintech and financial media expert. Rosen is former CEO of StockTwits.com, co-founder of Even Financial and former general manager of MarketWatch.

Throughout the interview, Rosen discussed business model changes that media companies must make in order to ensure their success going forward. 

The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me’s latest podcast features Ian Rosen, fintech and financial media expert. Rosen is former CEO of StockTwits.com, co-founder of Even Financial and former general manager of MarketWatch.

Throughout the interview, Rosen discussed business model changes that media companies must make in order to ensure their success going forward. 

The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me’s latest podcast features James Sapirstein, President & CEO of AzurRx BioPharma Inc. (NASDAQ: AZRX).

AzurRx currently has two ongoing clinical trials for MS1819. The first is a Phase 2 Cystic Fibrosis Combination Trial examining MS1819 in combination with PERT, which is expected to produce topline data in Q2 2021.

The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me’s latest podcast features James Sapirstein, President & CEO of AzurRx BioPharma Inc. (NASDAQ: AZRX).

AzurRx currently has two ongoing clinical trials for MS1819. The first is a Phase 2 Cystic Fibrosis Combination Trial examining MS1819 in combination with PERT, which is expected to produce topline data in Q2 2021.

Stock2Me’s latest podcast features John Truman Wolfe, number one best-selling and international award-winning author of The Coming Financial Crisis: A Look Behind the Wizard's Curtain and The 99 Strongest Banks in America. Wolfe is also the editor and publisher of Strategic Financial Intelligence, a monthly newsletter dealing with investing, politics and the economy.

Stock2Me’s latest podcast features John Truman Wolfe, number one best-selling and international award-winning author of The Coming Financial Crisis: A Look Behind the Wizard's Curtain and The 99 Strongest Banks in America. Wolfe is also the editor and publisher of Strategic Financial Intelligence, a monthly newsletter dealing with investing, politics and the economy.

Stock2Me’s latest podcast features Shawn Singh, CEO of VistaGen Therapeutics Inc. (NASDAQ: VTGN).

“Throughout the many years I’ve been in the [biopharma] space, I really haven’t been satisfied with the treatment alternatives that have been available to people all around the world who are suffering from mental illness, especially anxiety and depression,” Singh stated during the interview. “VistaGen provides, I think, an opportunity for tremendous excitement, given what we’re working on in our pipeline. We have three drug candidates focused on trying to go beyond the current standard of care for anxiety, depression and other CNS, or central nervous system, disorders.”

VistaGen’s lead drug candidate, PH94B, is a first-in-class neuroactive nasal spray that’s currently being developed as an acute treatment for anxiety in adults with Social Anxiety Disorder (SAD). Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA), positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with SAD, if planned Phase 3 studies are successful.

Stock2Me’s latest podcast features Shawn Singh, CEO of VistaGen Therapeutics Inc. (NASDAQ: VTGN).

“Throughout the many years I’ve been in the [biopharma] space, I really haven’t been satisfied with the treatment alternatives that have been available to people all around the world who are suffering from mental illness, especially anxiety and depression,” Singh stated during the interview. “VistaGen provides, I think, an opportunity for tremendous excitement, given what we’re working on in our pipeline. We have three drug candidates focused on trying to go beyond the current standard of care for anxiety, depression and other CNS, or central nervous system, disorders.”

VistaGen’s lead drug candidate, PH94B, is a first-in-class neuroactive nasal spray that’s currently being developed as an acute treatment for anxiety in adults with Social Anxiety Disorder (SAD). Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA), positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with SAD, if planned Phase 3 studies are successful.

Stock2Me’s latest podcast features Chris Lahiji, president of LD Micro, and Christopher Miglino, CEO and founder of SRAX Inc. (NASDAQ: SRAX).

The two executives joined the show to discuss the recent acquisition of LD Micro, a leading data and event company serving the small and micro-cap space, by SRAX, a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform, Sequire. SRAX announced the closing of the acquisition on September 16, 2020, noting that LD Micro will operate as a wholly owned subsidiary of SRAX and will continue to employ Lahiji, its founder, as its president.

Stock2Me’s latest podcast features Chris Lahiji, president of LD Micro, and Christopher Miglino, CEO and founder of SRAX Inc. (NASDAQ: SRAX).

The two executives joined the show to discuss the recent acquisition of LD Micro, a leading data and event company serving the small and micro-cap space, by SRAX, a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform, Sequire. SRAX announced the closing of the acquisition on September 16, 2020, noting that LD Micro will operate as a wholly owned subsidiary of SRAX and will continue to employ Lahiji, its founder, as its president.

The Stock2Me Podcast's latest episode features Oren Klaff, a recognized world leading expert on sales, negotiation and raising capital.

Oren has extensively studied how humans respond to each other in high-stakes business situations and pioneered the application of neuroscience into raising capital and capital markets programs. His first book, Pitch Anything, has become compulsory reading on Wall Street as well as throughout Silicon Valley and the Fortune 500. More than 1,000,000 copies of Pitch Anything are in print worldwide He also has written for Harvard Business Review, Inc., Advertising Age, Entrepreneur and has been featured in hundreds of periodicals, podcasts, and blogs. Oren is a member of Geyser Holding's investment committee and is Director of Capital Markets at Intersection Capital where he has supervised the placement of over $500 million of investor capital from high net-worth individuals and financial institutions.

The Stock2Me Podcast's latest episode features Oren Klaff, a recognized world leading expert on sales, negotiation and raising capital.

Oren has extensively studied how humans respond to each other in high-stakes business situations and pioneered the application of neuroscience into raising capital and capital markets programs. His first book, Pitch Anything, has become compulsory reading on Wall Street as well as throughout Silicon Valley and the Fortune 500. More than 1,000,000 copies of Pitch Anything are in print worldwide He also has written for Harvard Business Review, Inc., Advertising Age, Entrepreneur and has been featured in hundreds of periodicals, podcasts, and blogs. Oren is a member of Geyser Holding's investment committee and is Director of Capital Markets at Intersection Capital where he has supervised the placement of over $500 million of investor capital from high net-worth individuals and financial institutions.

Stock2Me’s latest podcast features Brant Pinvidic, an award-winning film director, veteran television producer, C-level sales and presentations coach, Forbes columnist and author of The 3-Minute Rule.

Brant Pinvidic leverages the life, business and storytelling lessons developed during his Hollywood career and uses them to uniquely bridge the entertainment industry and the business community. Over the course of 15 years as a television and film producer, Pinvidic created, developed, sold and produced more than 300 television projects across nearly every network, including smash hits like The Biggest Loser, Bar Rescue, Master Chef and Extreme Makeover: Weight Loss Edition.

Stock2Me’s latest podcast features Brant Pinvidic, an award-winning film director, veteran television producer, C-level sales and presentations coach, Forbes columnist and author of The 3-Minute Rule.

Brant Pinvidic leverages the life, business and storytelling lessons developed during his Hollywood career and uses them to uniquely bridge the entertainment industry and the business community. Over the course of 15 years as a television and film producer, Pinvidic created, developed, sold and produced more than 300 television projects across nearly every network, including smash hits like The Biggest Loser, Bar Rescue, Master Chef and Extreme Makeover: Weight Loss Edition.